Use of vincristine and cyclosporine in childhood thrombotic thrombocytopenic purpura

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 5, 2003, Pages 421-425

  Jayabose, Somasundaram ^a   Levendoglu Tugal, Oya ^b   Ozkayanak, M Fevzi ^b   Chao, Chun Peng ^b   Cuccovia, Barbara ^b   Sandoval, Claudio ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

Cyclosporine; Plasmapheresis; Systemic lupus erythematosus; Thrombotic thrombocytopenic purpura; Vincristine

Indexed keywords

ANTINUCLEAR ANTIBODY; CYCLOSPORIN; DNA ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ARTICLE; CASE REPORT; DIARRHEA; FEMALE; GRAND MAL SEIZURE; HEMOLYTIC UREMIC SYNDROME; HUMAN; MALE; MIXED CONNECTIVE TISSUE DISEASE; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; REMISSION; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING;

ADOLESCENT; CHILD; CYCLOSPORINE; FEMALE; HUMANS; MALE; PLASMAPHERESIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0037883547     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200305000-00015     Document Type: Article

References (33)

1. Ruggenenti P, Remuzzi G. Thrombotic thrombocytopenic purpura and related disorders. Hematol Oncol Clin North Am 1990;4:219.
2. Robinson WLM, Tsai H. Thrombotic thrombocytopenic purpura attributable to von Willebrand factor-cleaving protease inhibitor in an 8-year old boy. Pediatrics 2002:322-324.
3. Tsai HM, Chun-Yet Lian E. Antibodies to vWF cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594.
4. Furlan M, Robles R, Galbusera M. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med 1998;339:1578-1584.
5. Veyradier A, Obert B, Houllier A, et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001;98: 1765-1772.
6. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600.
7. Ruggenenti P, Remuzzi G. Pathophysiology and management of thrombotic microangiopathies. J Nephrol 1998;11:300-310.
8. Rock GA, Porta C. Thrombotic thrombocytopenic purpura in year 2000. Hematologica 2000;85:337-339.
9. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393-397.
10. Finazzi G, Bellavita P, Falanga A, et al. Inefficacy of intravenous immunoglobulin in patients with low-risk thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Am J Hematol 1992;41:165-169.
11. Welborn JL, Elmrick P, Acevedo M. Rapid improvement of thrombotic thrombocytopenic purpura with vincristine and plasmapheresis. Am J Hematol 1990; 35:18-21.
12. Hand JP, Lawlor ER, Yong CK, Davis JH. Successful use of cyclosporine A in the treatment of refractory thrombotic thrombocytopenic purpura. Br J Haematol 1998;100:597-599.
13. Chemnitz J, Draub A, Scheid C, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 2002;71:105-108.
14. Mant MJ, Turner AR, Ritchie DBC, Larratt LM. Splenectomy during partial remission in thrombotic thrombocytopenic purpura with prolonged plasma exchange dependency. Am J Hematol 1999;62:56-57.
15. Porta C, Bobbio-Pallavicini E, Centurioni R, Tacconi F. Thrombotic thrombocytopenic purpura resistant to plasma-exchange: salvage treatment with highdose IgG or vincristine. Italian Cooperative Group for TTP. Int J Artif Organs 1993(suppl 5):201-204.
16. George JN. How I treat patients with thrombotic thrombocytopenic purpurahemolytic uremic syndrome. Blood 2000;96:1223-1229.
17. Levin M, Grunwald HW. Use of vincristine in refractory thrombotic thrombocytopenic purpura. Acta Haematol 1991;885:37-40.
18. O'Connor NTJ, Bruce-Jones P, Hill LF. Vincristine therapy for thrombotic thrombocytopenic purpura. Am J Hematol 1992;39:234-236.
19. Bobbio-Pallavicini E, Porta C, Centurioni R, et al. Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasmaexchange. The Italian Cooperative Group for TTP. Eur J Hematol 1994;52:222-226.
20. Mazzel C, Pepkowitz S, Klapper E, et al. Treatment of thrombotic thrombocytopenic purpura: A role for early vincristine administration. J Clin Apheresis 1998;13:20-22.
21. Ferrara F, Copia C, Annnunziata M, et al. Vincristine as salvage treatment of refractory thrombotic thrombocytopenic purpura. Ann Hematol 1999;78:521-523.
22. Van Gool S, Brock P, Van Laer P, et al. Successful treatment of recurrent thrombotic thrombocytopenic purpura with plasmapheresis and vincristine. Eur J Pediatr 1994;153:517-519.
23. Bachman WR, Brennan JK. Refractory thrombotic thrombocytopenic purpura treated with cyclosporine. Am J Hematol 1996;51:93-94.
24. Kierdorf H, Maurin N, Heintz B. Cyclosporine for thrombotic thrombocytopenic purpura. Ann Intern Med 1993;118:987-988.
25. Van Ojik H, Biemsa DH, Fijnheer R, et al. Cyclosporine for thrombotic thrombocytopenic purpura after autologous bone marrow transplantation. Br J Haematol 1997;96:641-643.
26. Robertson JH, Crozier EH, Woodend BE. Vincristine therapy of thrombocytopenia. N Engl J Med 1975;292:108.
27. Gutterman LA. Thrombotic thrombocytopenic purpura: prospective treatment with a standard regimen. Transfus Sci 1992;13:45-52.
28. Sennet M, Conrad M. Treatment of thrombotic thrombocytopenic purpura. Plasmapheresis, plasma transfusion and vincristine. Arch Intern Med 1986;146:266-267.
29. Medina PJ, Sipols JM, George JG. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001;8:286-293.
30. Mori H, Wada H, Gabazza EZ, et al. Predicting response to plasma exchange inpatients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 2002;42:572-580.
31. Brunner H, Freedman M, Silverman E. Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood. Arthritis Rheum 1999;42:2346-2355.
32. Moore JC, Hayward CP, Warkentin TE, et al. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001;98: 1842-1846.
33. Vasoo S, Thumboo J, Fong KY. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: disease activity and the use of cytotoxic drugs. Lupus 2002;11:443-450.